RU2006146555A - INJECTED PHARMACEUTICAL COMPOSITIONS OF POSOCONAZOLE WITH STABILIZED PARTICLES - Google Patents
INJECTED PHARMACEUTICAL COMPOSITIONS OF POSOCONAZOLE WITH STABILIZED PARTICLES Download PDFInfo
- Publication number
- RU2006146555A RU2006146555A RU2006146555/15A RU2006146555A RU2006146555A RU 2006146555 A RU2006146555 A RU 2006146555A RU 2006146555/15 A RU2006146555/15 A RU 2006146555/15A RU 2006146555 A RU2006146555 A RU 2006146555A RU 2006146555 A RU2006146555 A RU 2006146555A
- Authority
- RU
- Russia
- Prior art keywords
- posaconazole
- composition according
- composition
- average
- max
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
1. Состав, содержащий позаконазол, фосфолипид, термозащитный агент и буферную систему.2. Состав по п.1, дополнительно содержащий воду.3. Состав по п.2, в котором указанный состав простерилизован автоклавированием.4. Состав по п.2, в котором указанный состав простерилизован облучением.5. Состав по п.1, в котором указанная буферная система содержит фосфат натрия.6. Состав по п.1, в котором указанная буферная система содержит органический буфер.7. Состав по п.1, в котором указанная буферная система содержит, по меньшей мере, один из гистидина, лимонной кислоты, глицина, цитрата натрия, сульфата аммония или уксусной кислоты.8. Состав по п.1, в котором указанная буферная система поддерживает значение рН в диапазоне от около 3,0 до около 9,0.9. Состав по п.1, в котором указанная буферная система поддерживает значение рН в диапазоне от около 6,0 до около 8,0.10. Состав по п.1, в котором указанная буферная система поддерживает значение рН в диапазоне от около 6,4 до около 7,6.11. Состав по п.1, в котором указанный фосфолипид содержит 1-пальмитоил-2-олеоил-sn-глицеро-3-фосфохолин (РОРС).12. Состав по п.1, в котором указанный термозащитный агент содержит трегалозу.13. Состав по п.2, в котором указанный фосфолипид содержит 1-пальмитоил-2-олеоил-sn-глицеро-3-фосфохолин (РОРС), указанный термозащитный агент содержит трегалозу, а указанная буферная система содержит фосфат натрия.14. Состав по п.1, в котором указанные частицы позаконазола характеризуются распределением размеров, среднее значение которого составляет от около 1,0 до около 8,0 мкм при содержании частиц размером 10 мкм или более, составляющем не более около 3000, и при содержании частиц размером 25 мкм или более, со1. Composition containing posaconazole, phospholipid, thermal protective agent and buffer system. 2. The composition according to claim 1, additionally containing water. The composition according to claim 2, wherein said composition is sterilized by autoclaving. The composition according to claim 2, wherein said composition is sterilized by radiation. The composition according to claim 1, wherein said buffer system contains sodium phosphate. The composition according to claim 1, wherein said buffer system contains an organic buffer. The composition according to claim 1, wherein said buffer system comprises at least one of histidine, citric acid, glycine, sodium citrate, ammonium sulfate or acetic acid. The composition according to claim 1, wherein said buffer system maintains a pH in the range from about 3.0 to about 9.0.9. The composition according to claim 1, in which the specified buffer system maintains a pH value in the range from about 6.0 to about 8.0.10. The composition according to claim 1, in which the specified buffer system maintains a pH value in the range from about 6.4 to about 7.6.11. The composition according to claim 1, wherein said phospholipid contains 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). The composition according to claim 1, wherein said thermoprotective agent contains trehalose. The composition according to claim 2, wherein said phospholipid contains 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), said heat shield agent contains trehalose, and said buffer system contains sodium phosphate. The composition according to claim 1, in which the indicated particles of posaconazole are characterized by a size distribution, the average value of which is from about 1.0 to about 8.0 microns with a content of particles of 10 microns or more, comprising not more than about 3000, and with a content of particles of size 25 microns or more, with
Claims (59)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57512604P | 2004-05-28 | 2004-05-28 | |
US60/575,126 | 2004-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006146555A true RU2006146555A (en) | 2008-07-20 |
Family
ID=34971355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006146555/15A RU2006146555A (en) | 2004-05-28 | 2005-05-27 | INJECTED PHARMACEUTICAL COMPOSITIONS OF POSOCONAZOLE WITH STABILIZED PARTICLES |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1761247A1 (en) |
JP (1) | JP2008501034A (en) |
KR (1) | KR20070027564A (en) |
CN (1) | CN1988887A (en) |
AR (1) | AR049063A1 (en) |
AU (1) | AU2005249502A1 (en) |
CA (1) | CA2567803A1 (en) |
IL (1) | IL179627A0 (en) |
MX (1) | MXPA06013886A (en) |
NO (1) | NO20066005L (en) |
PE (1) | PE20060291A1 (en) |
RU (1) | RU2006146555A (en) |
TW (1) | TWI290051B (en) |
WO (1) | WO2005117831A1 (en) |
ZA (1) | ZA200609890B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060009469A1 (en) * | 2004-05-28 | 2006-01-12 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
RU2008148977A (en) | 2006-05-12 | 2010-06-20 | Фармакон-Форшунг Унд Бератунг Гмбх (At) | APPLICATION OF COMBINED DRUGS CONTAINING ANTIFUNGIC AGENTS |
EP2130540A1 (en) | 2008-06-02 | 2009-12-09 | Sandoz AG | Pharmaceutical compositions containing a crystalline form of posaconazole |
EP2141159A1 (en) | 2008-07-03 | 2010-01-06 | Sandoz AG | A Crystalline form of posaconazole |
CA2767489A1 (en) | 2009-07-09 | 2011-01-13 | Sandoz Ag | A crystalline form of posaconazole |
JP5956980B2 (en) | 2010-05-19 | 2016-07-27 | サンド・アクチエンゲゼルシヤフト | Process for the preparation of chiral compounds |
EP2571871B1 (en) | 2010-05-19 | 2017-06-21 | Sandoz AG | Process for the preparation of chiral triazolones |
US9073904B2 (en) | 2010-05-19 | 2015-07-07 | Sandoz Ag | Preparation of posaconazole intermediates |
CA2798010C (en) | 2010-05-19 | 2018-09-25 | Sandoz Ag | Purification of posaconazole and of posaconazole intermediates |
RS62583B1 (en) | 2010-06-29 | 2021-12-31 | Merck Sharp & Dohme | Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin |
CN108329303A (en) | 2011-06-16 | 2018-07-27 | 桑多斯股份公司 | The method for preparing chipal compounds |
CN103284959B (en) * | 2012-02-22 | 2015-06-03 | 重庆圣华曦药业股份有限公司 | Posaconazole freeze-dried powder injection and preparation method thereof |
CN102755628B (en) * | 2012-07-16 | 2013-10-23 | 中国科学院微生物研究所 | Antifungal pharmaceutical composition |
CN102805731B (en) * | 2012-08-22 | 2014-04-30 | 北京莱瑞森医药科技有限公司 | Posaconazole dry suspension and preparation method thereof |
CN105030668B (en) * | 2015-06-26 | 2018-03-27 | 济川药业集团有限公司 | Oral posaconazole supensoid agent and preparation method thereof |
CN106333925B (en) * | 2015-07-10 | 2019-06-18 | 上海美悦生物科技发展有限公司 | A kind of posaconazole liquid suspension and preparation method thereof |
CN105997872B (en) * | 2016-07-08 | 2019-02-19 | 河南省立眼科医院 | A kind of antimycotic solution of ophthalmically acceptable nano-micelle containing posaconazole |
CA3056919A1 (en) * | 2017-03-26 | 2018-10-04 | Vivi Robyn Stafford | Method of treatment of skin conditions of eye lids |
AU2018253189A1 (en) * | 2017-04-12 | 2019-12-05 | Vikash J. BHAGWANDIN | Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors |
CN110507609B (en) * | 2018-05-21 | 2021-09-17 | 上海医药工业研究院 | Preparation method of posaconazole oral suspension |
CN111514146A (en) * | 2020-04-28 | 2020-08-11 | 山西振东泰盛制药有限公司 | Pharmaceutical composition containing posaconazole |
CN113933131B (en) * | 2021-09-24 | 2024-01-26 | 合肥天一生物技术研究所有限责任公司 | Vaginal microorganism fluorescent staining solution |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
JP4308902B2 (en) * | 2001-04-03 | 2009-08-05 | シェーリング コーポレイション | Antifungal compositions with increased bioavailability |
-
2005
- 2005-05-27 TW TW094117524A patent/TWI290051B/en not_active IP Right Cessation
- 2005-05-27 AR ARP050102203A patent/AR049063A1/en not_active Application Discontinuation
- 2005-05-27 CN CNA2005800248542A patent/CN1988887A/en active Pending
- 2005-05-27 KR KR1020067024996A patent/KR20070027564A/en not_active Application Discontinuation
- 2005-05-27 EP EP05755118A patent/EP1761247A1/en not_active Withdrawn
- 2005-05-27 CA CA002567803A patent/CA2567803A1/en not_active Abandoned
- 2005-05-27 JP JP2007515456A patent/JP2008501034A/en not_active Withdrawn
- 2005-05-27 MX MXPA06013886A patent/MXPA06013886A/en unknown
- 2005-05-27 WO PCT/US2005/018945 patent/WO2005117831A1/en active Application Filing
- 2005-05-27 AU AU2005249502A patent/AU2005249502A1/en not_active Abandoned
- 2005-05-27 PE PE2005000599A patent/PE20060291A1/en not_active Application Discontinuation
- 2005-05-27 RU RU2006146555/15A patent/RU2006146555A/en not_active Application Discontinuation
-
2006
- 2006-11-27 ZA ZA200609890A patent/ZA200609890B/en unknown
- 2006-11-27 IL IL179627A patent/IL179627A0/en unknown
- 2006-12-22 NO NO20066005A patent/NO20066005L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20060291A1 (en) | 2006-04-14 |
EP1761247A1 (en) | 2007-03-14 |
JP2008501034A (en) | 2008-01-17 |
TW200609001A (en) | 2006-03-16 |
AR049063A1 (en) | 2006-06-21 |
CA2567803A1 (en) | 2005-12-15 |
CN1988887A (en) | 2007-06-27 |
KR20070027564A (en) | 2007-03-09 |
AU2005249502A1 (en) | 2005-12-15 |
ZA200609890B (en) | 2008-09-25 |
MXPA06013886A (en) | 2007-01-26 |
TWI290051B (en) | 2007-11-21 |
NO20066005L (en) | 2007-02-27 |
WO2005117831A1 (en) | 2005-12-15 |
IL179627A0 (en) | 2007-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006146555A (en) | INJECTED PHARMACEUTICAL COMPOSITIONS OF POSOCONAZOLE WITH STABILIZED PARTICLES | |
US8551942B2 (en) | Lyophilized anti-fungal compositions | |
US8431539B2 (en) | Formulations of daptomycin | |
US20220323539A1 (en) | Compositions and methods for the treatment of fungal infections | |
US8980827B2 (en) | Medicinal composition containing echinocandin antifungal agent micafungin and preparation method and use thereof | |
US9662342B2 (en) | Formulations of cyclophosphamide liquid concentrate | |
US11931362B2 (en) | Stable pharmaceutical formulations of pemetrexed | |
ES2298821T3 (en) | USE OF AN ANTIFUNGIC EQUINOCANDINE AGENT IN COMBINATION WITH AN ANTIBACTERIAL GLICOPEPTIDIC AGENT. | |
NZ516108A (en) | Ophthalmic composition containing ketotifen and a non-ionic tonicity agent | |
CN101637447B (en) | Sitafloxacin hydrate injection and preparation method thereof | |
CN112569229A (en) | Preparation containing ornidazole compound and preparation method and application thereof | |
TW200423871A (en) | Topical parasiticide formulations and methods of treatment | |
TW201842911A (en) | The therapeutic regimen | |
JP2007535545A (en) | Formulation for oral administration of poorly absorbable drugs | |
US6699847B2 (en) | Antiparasitic formulation | |
CN114886908A (en) | Medical application of echinacoside | |
US20100210681A1 (en) | Aqueous pharmaceutical composition | |
US20210315898A1 (en) | Combination therapy for treating cancer | |
AU2019328599A1 (en) | Compounds and methods for treating fungal infections | |
RU2008108216A (en) | PHARMACEUTICAL DOSED FORMS AND COMPOSITIONS CONTAINING LEKOSOTAN | |
CN116251168A (en) | Pharmaceutical composition of echinocandin analogue and preparation method thereof | |
SK8702001A3 (en) | Cyclosporin solution | |
OA20177A (en) | Compounds and methods for treating fungal infections. | |
JP3022915B2 (en) | Cancer metastasis inhibitor | |
UA124498C2 (en) | Pharmaceutical composition for topical application for treating infectious inflammatory diseases, and method for producing and using same (variants) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090929 |